CTD²: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD2) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy. 

Banner for CTD squared program. Links to CTD squared program page
Last updated: July 01, 2020

News & Publications

previousnext
Immune System Illustration
CTD²
August 20, 2020

Natural killer (NK) cells belong to the innate immune system and contribute to protecting the host through killing of infected, foreign, stressed or transformed cells. Additionally, via cellular cross-talk, NK cells orchestrate antitumor immune responses. Hence, significant efforts have been...

Imputation RMSE on the gene expression data for MCAR cases of 5%, 10%, and 30%
CTD²
August 01, 2020

Background: As missing values are frequently present in genomic data, practical methods to handle missing data are necessary for downstream analyses that require complete data sets. State-of-the-art imputation techniques, including methods based on singular value decomposition...

Human breast tumor organoid invades collectively into a 3D collagen I microenvironment
CTD²
August 01, 2020

Cancer invasion and metastasis are challenging to study in vivo since they occur deep inside the body over extended time periods. Organotypic 3D culture of fresh tumor tissue enables convenient real-time imaging, genetic and microenvironmental manipulation and molecular analysis. Here, we...

Tumor Organoid Culture Systems Modeling the Tumor Immune Microenvironment
CTD²
August 01, 2020

Cellular interactions in the tumor microenvironment (TME) significantly govern cancer progression and drug response. The efficacy of clinical immunotherapies has fostered an exponential interest in the tumor immune microenvironment, which in turn has engendered a pressing need for robust...

CTD²
July 27, 2020

We give results from a detailed analysis of human Ribosomal Protein (RP) levels in normal and cancer samples and cell lines from large mRNA, copy number variation and ribosome profiling datasets. After normalizing total RP mRNA levels per sample, we find highly consistent tissue specific RP mRNA...

O
O
O
O
O